Our global portfolio has approximately 1,400 molecules across a broad range of therapeutic areas spanning non-communicable and infectious diseases, including brand-name products, generics and OTC medicines.
Globally we are a provider of biosimilars, an industry we helped found, with more than 150 marketing approvals for biosimilars in more than 85 countries.
Our diverse portfolio delivers trusted, quality medicines that treat nine out of 10 of the World Health Organization’s (WHO) leading causes of death and more than 200 of our medicines are on the WHO Essential Medicines List.
We are a leading supplier of medicines to the HIV/AIDS community around the world, with a legacy of providing access to high quality and affordable antiretrovirals in more than 100 countries.
- We are a leading supplier of medicines to the HIV/AIDS community, providing access to high quality and affordable antiretrovirals in over 100 countries. Approximately 40% of the 23.31 million people on treatment for HIV use our products.
- In Australia we supported a major trial of pre-exposure prophylaxis medication for HIV/AIDS which led to its PBS reimbursement ensuring this valuable prevention therapy is affordable.
- Our new state-of-the-art warehouse and distribution centre in Bundamba, Queensland stores extensive volumes of stock and a wide range of critical products under one roof. An order can be shipped from there to anywhere around the country overnight.
- In Australia many of our employees are highly qualified in engineering, science and pharmacy. Of almost 600 employees at our Carole Park, Queensland manufacturing site, over 220 have a degree or higher qualification and over 25 have a trade qualification.